Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplant: A case control study

Medicine & Life Sciences

• Immunoglobulin Light-chain Amyloidosis 100%
• Peripheral Blood Stem Cells 94%
• Case-Control Studies 59%
• Transplants 46%
• Survival 41%
• Amyloidosis 33%
• Stroke Volume 26%
• Creatinine 23%
• Paraproteinemias 18%
• Drug Therapy 17%
• National Cancer Institute (U.S.) 17%
• Selection Bias 17%
• Hematology 15%
• Peripheral Nerves 14%
• Serum 13%
• Alkaline Phosphatase 13%
• Blood Proteins 13%
• Survival Rate 11%
• Bone Marrow 10%
• Urine 10%
• Randomized Controlled Trials 10%
• Control Groups 7%
• Neoplasms 4%